Packaging
Stora Enso signs Pharma DDS licence agreement with Enestia
Wednesday 08. April 2009 - Stora Enso has signed a licence agreement with Enestia Belgium NV/SA regarding the contract packaging of pharmaceutical products in Pharma DDS cartons. The increasing availability of contract packaging services enables pharmaceutical companies to run the Pharma DDS packaging solution for their products worldwide.
Enestia is a subsidiary of the Irish company United Drug plc, as is Sharp Corporation in the US which also has a Pharma DDS license agreement with Stora Enso. These license agreements ensure the availability of the Pharma DDS packaging solution across Europe and North America. Stora Enso also has accredited printers to produce the printed and converted blanks of the Pharma DDS carton.
“Our partnership with the two United Drug subsidiaries will significantly broaden the availability of Pharma DDS contract packaging services, now covering the European and North American markets. Logistical and commercial benefits for pharmaceutical brand owners are evident as they can now easily employ the same packaging solution globally. Pharma DDS is targeted for both prescription drugs and over-the-counter products, and it meets the stringent US and European child-resistance demands,” says Ismo Saarinen of Stora Enso.
“As we have broad experience of various packaging concepts, we see the Pharma DDS carton as an extension of our capabilities and offerings using slightly modified existing equipment,” says Ludwig Bastiaansen of Enestia.
The Pharma DDS carton has several features that support the patient’s compliance with his or her drug prescription. The carton is convenient and discreet to use, yet it has reached the highest F=1 child-resistance testing result. It has a unique locking mechanism and can be produced in a variety of sizes and versions, which makes it suitable for a wide range of unit dose packaging. Thanks to the effective production technique, a competitive cost level can be achieved for both small and high volume drugs.